IL3RA and neoplasm: Given anticipated on-target off-tumor activity against HPCs, CD123-CAR T cell trials have incorporated additional measures to ensure safety, including incorporating bridge-to-transplant options and safety switches to “turn off” CAR T cells after desired activity to avoid toxicity to infused HPCs after bone marrow transplant [77,79].